Dipeptidyl peptidase-4 independent cardiac dysfunction links saxagliptin to heart failure

Biochemical Pharmacology

Volumn 145, Issue , 2017, Pages 64-80

  Koyani, Chintan N ^a   Kolesnik, Ewald ^a   Wölkart, Gerald ^b   Shrestha, Niroj ^a   Scheruebel, Susanne ^a   Trummer, Christopher ^a   Zorn Pauly, Klaus ^a   Hammer, Astrid ^a   Lang, Petra ^a   Reicher, Helga ^a   Maechler, Heinrich ^a   Groschner, Klaus ^a   Mayer, Bernd ^b   Rainer, Peter P ^a   Sourij, Harald ^a,c   Sattler, Wolfgang ^a   Malle, Ernst ^a   Pelzmann, Brigitte ^a   von Lewinski, Dirk ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF GRAZ   (Austria)

^c Center for Biomarker Research in Medicine   (Austria)

Author keywords

Ca2+ transient; CaMKII; DPP 4; Na+ Ca2+ exchanger; Protein kinase C; SERCA2a

Indexed keywords

CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; DIPEPTIDYL PEPTIDASE IV; PROTEIN KINASE C; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SAXAGLIPTIN; ADAMANTANE; DIPEPTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR;

AGED; ANIMAL CELL; ARTICLE; CARDIAC MUSCLE CELL; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GUINEA PIG; HEART DISEASE; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART TRABECULAR MUSCLE; HEART VENTRICLE OVERLOAD; HUMAN; HUMAN TISSUE; MALE; MOUSE; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; SODIUM CALCIUM EXCHANGE; SYSTOLIC DYSFUNCTION; ANALOGS AND DERIVATIVES; ANIMAL; CELL LINE; CYTOLOGY; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HEART ATRIUM; HEART CONTRACTION; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

ADAMANTANE; AGED; ANIMALS; CELL LINE; DIPEPTIDES; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEART ATRIA; HEART DISEASES; HUMANS; MALE; MICE; MIDDLE AGED; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC;

EID: 85028767011     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2017.08.021     Document Type: Article

References (80)

1. International Diabetes Federation, 2015.
2. Peter, R., Cox, A., Evans, M., Management of diabetes in cardiovascular patients: diabetic heart disease. Heart 94:3 (2008), 369–375.
3. Lam, C.S., Diabetic cardiomyopathy: an expression of stage B heart failure with preserved ejection fraction. Diab. Vasc. Dis. Res. 12:4 (2015), 234–238.
4. McMurray, J.J., Gerstein, H.C., Holman, R.R., Pfeffer, M.A., Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol. 2:10 (2014), 843–851.
5. Kasznicki, J., Drzewoski, J., Heart failure in the diabetic population – pathophysiology, diagnosis and management. Arch. Med. Sci. 10:3 (2014), 546–556.
6. Miki, T., Yuda, S., Kouzu, H., Miura, T., Diabetic cardiomyopathy: pathophysiology and clinical features. Heart Fail Rev. 18:2 (2013), 149–166.
7. Mandinov, L., Eberli, F.R., Seiler, C., Hess, O.M., Diastolic heart failure. Cardiovasc. Res. 45:4 (2000), 813–825.
8. Bleske, B.E., Evolution and pathophysiology of chronic systolic heart failure. Pharmacotherapy 20:11 Pt 2 (2000), 349S–358S.
9. Teupe, C., Rosak, C., Diabetic cardiomyopathy and diastolic heart failure – difficulties with relaxation. Diabetes Res. Clin. Pract. 97:2 (2012), 185–194.
10. von Bibra, H., John Sutton, M.St., Diastolic dysfunction in diabetes and the metabolic syndrome: promising potential for diagnosis and prognosis. Diabetologia 53:6 (2010), 1033–1045.
11. Wang, Y., Hill, J.A., Electrophysiological remodeling in heart failure. J. Mol. Cell Cardiol. 48:4 (2010), 619–632.
12. Udell, J.A., Cavender, M.A., Bhatt, D.L., Chatterjee, S., Farkouh, M.E., Scirica, B.M., Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 3:5 (2015), 356–366.
13. Stein, S.A., Lamos, E.M., Davis, S.N., A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf. 12:2 (2013), 153–175.
14. Boulton, D.W., Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor. Clin. Pharmacokinet., 2016.
15. Green, J.B., Bethel, M.A., Armstrong, P.W., Buse, J.B., Engel, S.S., Garg, J., Josse, R., Kaufman, K.D., Koglin, J., Korn, S., Lachin, J.M., McGuire, D.K., Pencina, M.J., Standl, E., Stein, P.P., Suryawanshi, S., Van de, F., Werf, Peterson, E.D., Holman, R.R., Group, T.S., Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 373:3 (2015), 232–242.
16. Zannad, F., Cannon, C.P., Cushman, W.C., Bakris, G.L., Menon, V., Perez, A.T., Fleck, P.R., Mehta, C.R., Kupfer, S., Wilson, C., Lam, H., White, W.B., Investigators, E., Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 385:9982 (2015), 2067–2076.
17. Scirica, B.M., Bhatt, D.L., Braunwald, E., Steg, P.G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S.D., Hoffman, E.B., Cavender, M.A., Udell, J.A., Desai, N.R., Mosenzon, O., McGuire, D.K., Ray, K.K., Leiter, L.A., Raz, I., Committee, S.-T.S., Investigators, Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 369:14 (2013), 1317–1326.
18. U.S. Food and Drug Administration, 2016. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494252.htm.
19. Koyani, C.N., Windischhofer, W., Rossmann, C., Jin, G., Kickmaier, S., Heinzel, F.R., Groschner, K., Alavian-Ghavanini, A., Sattler, W., Malle, E., 15-deoxy-Delta(1)(2), (1)(4)-PGJ(2) promotes inflammation and apoptosis in cardiomyocytes via the DP2/MAPK/TNFalpha axis. Int. J. Cardiol. 173:3 (2014), 472–480.
20. von Lewinski, D., Kockskamper, J., Rubertus, S.U., Zhu, D., Schmitto, J.D., Schondube, F.A., Hasenfuss, G., Pieske, B., Direct pro-arrhythmogenic effects of angiotensin II can be suppressed by AT1 receptor blockade in human atrial myocardium. Eur. J. Heart Fail. 10:12 (2008), 1172–1176.
21. von Lewinski, D., Kockskamper, J., Zhu, D., Post, H., Elgner, A., Pieske, B., Reduced stretch-induced force response in failing human myocardium caused by impaired Na(+)-contraction coupling. Circ. Heart Fail. 2:1 (2009), 47–55.
22. Wallner, M., Kolesnik, E., Ablasser, K., Khafaga, M., Wakula, P., Ljubojevic, S., Thon-Gutschi, E.M., Sourij, H., Kapl, M., Edmunds, N.J., Kuzmiski, J.B., Griffith, D.A., Knez, I., Pieske, B., von Lewinski, D., Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium: GLP-1R mediated effects in human myocardium. J. Mol. Cell Cardiol. 89:Pt B (2015), 365–375.
23. Wölkart, G., Wenzl, M.V., Beretta, M., Stessel, H., Schmidt, K., Mayer, B., Vascular tolerance to nitroglycerin in ascorbate deficiency. Cardiovasc. Res. 79:2 (2008), 304–312.
24. Pelzmann, B., Hallstrom, S., Schaffer, P., Lang, P., Nadlinger, K., Birkmayer, G.D., Vrecko, K., Reibnegger, G., Koidl, B., NADH supplementation decreases pinacidil-primed I K ATP in ventricular cardiomyocytes by increasing intracellular ATP. Br. J. Pharmacol. 139:4 (2003), 749–754.
25. Scheruebel, S., Koyani, C.N., Hallstrom, S., Lang, P., Platzer, D., Machler, H., Lohner, K., Malle, E., Zorn-Pauly, K., Pelzmann, B., I(f) blocking potency of ivabradine is preserved under elevated endotoxin levels in human atrial myocytes. J. Mol. Cell Cardiol. 72 (2014), 64–73.
26. Zorn-Pauly, K., Schaffer, P., Pelzmann, B., Bernhart, E., Wei, G., Lang, P., Ledinski, G., Greilberger, J., Koidl, B., Jurgens, G., Oxidized LDL induces ventricular myocyte damage and abnormal electrical activity–role of lipid hydroperoxides. Cardiovasc. Res. 66:1 (2005), 74–83.
27. Pelzmann, B., Schaffer, P., Bernhart, E., Lang, P., Machler, H., Rigler, B., Koidl, B., L-type calcium current in human ventricular myocytes at a physiological temperature from children with tetralogy of Fallot. Cardiovasc. Res. 38:2 (1998), 424–432.
28. Wölkart, G., Schrammel, A., Koyani, C.N., Scherubel, S., Zorn-Pauly, K., Malle, E., Pelzmann, B., Andra, M., Ortner, A., Mayer, B., Cardioprotective effects of 5-hydroxymethylfurfural mediated by inhibition of L-type Ca2+ current. Br. J. Pharmacol., 2017, 10.1111/bph.13967.
29. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260:6 (1985), 3440–3450.
30. Palmer, B.M., Moore, R.L., Excitation wavelengths for fura 2 provide a linear relationship between [Ca(2+)] and fluorescence ratio. Am. J. Physiol. Cell Physiol. 279:4 (2000), C1278–C1284.
31. Tekkeli, S., Kiziltas, M., Dincel, D., An HPLC method for the determination of saxagliptin in human plasma with fluorescence detection. J. Adv. Chem. 5:3 (2009), 810–818.
32. Koyani, C.N., Kitz, K., Rossmann, C., Bernhart, E., Huber, E., Trummer, C., Windischhofer, W., Sattler, W., Malle, E., Activation of the MAPK/Akt/Nrf2-Egr1/HO-1-GCLc axis protects MG-63 osteosarcoma cells against 15d-PGJ2-mediated cell death. Biochem. Pharmacol. 104 (2016), 29–41.
33. Green, B., Flatt, P., Bailey, C., Gliptins: DPP-4 inhibitors to treat type 2 diabetes. Future Prescriber. 8:3 (2007), 6–12.
34. Thomas, L., Eckhardt, M., Langkopf, E., Tadayyon, M., Himmelsbach, F., Mark, M., (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylm ethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J. Pharmacol. Exp. Ther. 325:1 (2008), 175–182.
35. Shigeta, T., Aoyama, M., Bando, Y.K., Monji, A., Mitsui, T., Takatsu, M., Cheng, X.W., Okumura, T., Hirashiki, A., Nagata, K., Murohara, T., Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions. Circulation 126:15 (2012), 1838–1851.
36. Udenfriend, S., Stein, S., Bohlen, P., Dairman, W., Leimgruber, W., Weigele, M., Fluorescamine: a reagent for assay of amino acids, peptides, proteins, and primary amines in the picomole range. Science 178:4063 (1972), 871–872.
37. Bers, D.M., Calcium fluxes involved in control of cardiac myocyte contraction. Circ. Res. 87:4 (2000), 275–281.
38. Clusin, W.T., Caffeine induces a transient inward current in cultured cardiac cells. Nature 301:5897 (1983), 248–250.
39. Hess, P., Wier, W.G., Excitation-contraction coupling in cardiac Purkinje fibers. Effects of caffeine on the intracellular [Ca2+] transient, membrane currents, and contraction. J. Gen. Physiol. 83:3 (1984), 417–433.
40. Bassani, J.W., Bassani, R.A., Bers, D.M., Relaxation in rabbit and rat cardiac cells: species-dependent differences in cellular mechanisms. J. Physiol. 476:2 (1994), 279–293.
41. Choi, H.S., Eisner, D.A., The role of sarcolemmal Ca2+-ATPase in the regulation of resting calcium concentration in rat ventricular myocytes. J. Physiol. 515:Pt 1 (1999), 109–118.
42. MacLennan, D.H., Kranias, E.G., Phospholamban: a crucial regulator of cardiac contractility. Nat. Rev. Mol. Cell Biol. 4:7 (2003), 566–577.
43. Mattiazzi, A., Kranias, E.G., The role of CaMKII regulation of phospholamban activity in heart disease. Front Pharmacol., 5, 2014, 5.
44. di Bernardo, D., Langley, P., Murray, A., Effect of changes in heart rate and in action potential duration on the electrocardiogram T wave shape. Physiol. Meas. 23:2 (2002), 355–364.
45. Brouillette, J., Lupien, M.A., St-Michel, C., Fiset, C., Characterization of ventricular repolarization in male and female guinea pigs. J. Mol. Cell Cardiol. 42:2 (2007), 357–366.
46. Walsh, K.B., Kass, R.S., Regulation of a heart potassium channel by protein kinase A and C. Science 242:4875 (1988), 67–69.
47. Das, S.R., Drazner, M.H., Yancy, C.W., Stevenson, L.W., Gersh, B.J., Dries, D.L., Effects of diabetes mellitus and ischemic heart disease on the progression from asymptomatic left ventricular dysfunction to symptomatic heart failure: a retrospective analysis from the Studies of Left Ventricular Dysfunction (SOLVD) Prevention trial. Am. Heart J. 148:5 (2004), 883–888.
48. Scirica, B.M., Braunwald, E., Raz, I., Cavender, M.A., Morrow, D.A., Jarolim, P., Udell, J.A., Mosenzon, O., Im, K., Umez-Eronini, A.A., Pollack, P.S., Hirshberg, B., Frederich, R., Lewis, B.S., McGuire, D.K., Davidson, J., Steg, P.G., Bhatt, D.L., Committee, S.-T.S., Investigators*, Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 130:18 (2014), 1579–1588.
49. Onglyza® (saxagliptin), 2016. http://www.azpicentral.com/onglyza/pi_onglyza.pdf#page=1.
50. Luo, M., Anderson, M.E., Mechanisms of altered Ca(2)(+) handling in heart failure. Circ. Res. 113:6 (2013), 690–708.
51. Anderson, M.E., Brown, J.H., Bers, D.M., CaMKII in myocardial hypertrophy and heart failure. J. Mol. Cell Cardiol. 51:4 (2011), 468–473.
52. Palaniyandi, S.S., Sun, L., Ferreira, J.C., Mochly-Rosen, D., Protein kinase C in heart failure: a therapeutic target?. Cardiovasc. Res. 82:2 (2009), 229–239.
53. Hasenfuss, G., Reinecke, H., Studer, R., Meyer, M., Pieske, B., Holtz, J., Holubarsch, C., Posival, H., Just, H., Drexler, H., Relation between myocardial function and expression of sarcoplasmic reticulum Ca(2+)-ATPase in failing and nonfailing human myocardium. Circ. Res. 75:3 (1994), 434–442.
54. Pieske, B., Maier, L.S., Bers, D.M., Hasenfuss, G., Ca2+ handling and sarcoplasmic reticulum Ca2+ content in isolated failing and nonfailing human myocardium. Circ. Res. 85:1 (1999), 38–46.
55. Pogwizd, S.M., Qi, M., Yuan, W., Samarel, A.M., Bers, D.M., Upregulation of Na(+)/Ca(2+) exchanger expression and function in an arrhythmogenic rabbit model of heart failure. Circ. Res. 85:11 (1999), 1009–1019.
56. Bers, D.M., Eisner, D.A., Valdivia, H.H., Sarcoplasmic reticulum Ca2+ and heart failure: roles of diastolic leak and Ca2+ transport. Circ. Res. 93:6 (2003), 487–490.
57. Eisner, D., Caldwell, J., Trafford, A., Sarcoplasmic reticulum Ca-ATPase and heart failure 20 years later. Circ. Res. 113:8 (2013), 958–961.
58. Braunwald, E., Heart failure. JACC Heart Fail. 1:1 (2013), 1–20.
59. Periasamy, M., Janssen, P.M., Molecular basis of diastolic dysfunction. Heart Fail Clin. 4:1 (2008), 13–21.
60. Asp, M.L., Martindale, J.J., Heinis, F.I., Wang, W., Metzger, J.M., Calcium mishandling in diastolic dysfunction: mechanisms and potential therapies. Biochim. Biophys. Acta. 1833:4 (2013), 895–900.
61. Dibb, K.M., Graham, H.K., Venetucci, L.A., Eisner, D.A., Trafford, A.W., Analysis of cellular calcium fluxes in cardiac muscle to understand calcium homeostasis in the heart. Cell Calcium. 42:4–5 (2007), 503–512.
62. 2+ ATPase and phospholamban mRNA and protein levels in end-stage heart failure due to ischemic or dilated cardiomyopathy. J Mol Med (Berl). 74:6 (1996), 321–332.
63. Reinecke, H., Studer, R., Vetter, R., Holtz, J., Drexler, H., Cardiac Na+/Ca2+ exchange activity in patients with end-stage heart failure. Cardiovasc. Res. 31:1 (1996), 48–54.
64. 2+-exchanger protein levels and diastolic function of failing human myocardium. Circulation 99:5 (1999), 641–648.
65. Bursi, F., Weston, S.A., Redfield, M.M., Jacobsen, S.J., Pakhomov, S., Nkomo, V.T., Meverden, R.A., Roger, V.L., Systolic and diastolic heart failure in the community. JAMA. 296:18 (2006), 2209–2216.
66. Singh, R.M., Cummings, E., Pantos, C., Singh, J., Protein kinase C and cardiac dysfunction: a review. Heart Fail Rev., 2017, 10.1007/s10741-017-9634-3.
67. Munakata, M., Stamm, C., Friehs, I., Zurakowski, D., Cowan, D.B., Cao-Danh, H., McGowan, F.X. Jr., del Nido, P.J., Protective effects of protein kinase C during myocardial ischemia require activation of phosphatidyl-inositol specific phospholipase C. Ann. Thorac. Surg. 73:4 (2002), 1236–1245.
68. Belmonte, S.L., Blaxall, B.C., PKC-ing is believing: targeting protein kinase C in heart failure. Circ. Res. 109:12 (2011), 1320–1322.
69. Nabauer, M., Kaab, S., Potassium channel down-regulation in heart failure. Cardiovasc. Res. 37:2 (1998), 324–334.
70. Zhang, H., Hancox, J.C., In silico study of action potential and QT interval shortening due to loss of inactivation of the cardiac rapid delayed rectifier potassium current. Biochem. Biophys. Res. Commun. 322:2 (2004), 693–699.
71. Wickenden, A.D., Kaprielian, R., Kassiri, Z., Tsoporis, J.N., Tsushima, R., Fishman, G.I., Backx, P.H., The role of action potential prolongation and altered intracellular calcium handling in the pathogenesis of heart failure. Cardiovasc. Res. 37:2 (1998), 312–323.
72. Bouchard, R.A., Clark, R.B., Giles, W.R., Effects of action potential duration on excitation-contraction coupling in rat ventricular myocytes Action potential voltage-clamp measurements. Circ. Res. 76:5 (1995), 790–801.
73. Bouchard, R.A., Clark, R.B., Giles, W.R., Role of sodium-calcium exchange in activation of contraction in rat ventricle. J. Physiol. 472 (1993), 391–413.
74. D.W. Boulton, M. Geraldes, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Once-Daily Oral Doses of Saxagliptin for 2 Weeks in Type 2 Diabetic and Healthy Subjects (Poster 0606-P), 67th Scientific Sessions, Diabetes, 2007, p. A161.
75. Bloomfield, D.M., Krishna, R., Hreniuk, D., Hickey, L., Ghosh, K., Bergman, A.J., Miller, J., Gutierrez, M.J., Stoltz, R., Gottesdiener, K.M., Herman, G.A., Wagner, J.A., A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects. J. Clin. Pharmacol. 49:8 (2009), 937–946.
76. Ring, A., Port, A., Graefe-Mody, E.U., Revollo, I., Iovino, M., Dugi, K.A., The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses. Br. J. Clin. Pharmacol. 72:1 (2011), 39–50.
77. Kishimoto, M., Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes. Diabetes Metab. Syndr. Obes. 6 (2013), 187–195.
78. Boulton, D.W., Li, L., Frevert, E.U., Tang, A., Castaneda, L., Vachharajani, N.N., Kornhauser, D.M., Patel, C.G., Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin. Pharmacokinet. 50:4 (2011), 253–265.
79. Matsubara, J., Sugiyama, S., Sugamura, K., Nakamura, T., Fujiwara, Y., Akiyama, E., Kurokawa, H., Nozaki, T., Ohba, K., Konishi, M., Maeda, H., Izumiya, Y., Kaikita, K., Sumida, H., Jinnouchi, H., Matsui, K., Kim-Mitsuyama, S., Takeya, M., Ogawa, H., A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J. Am. Coll. Cardiol. 59:3 (2012), 265–276.
80. Mason, R.P., Jacob, R.F., Kubant, R., Walter, M.F., Bellamine, A., Jacoby, A., Mizuno, Y., Malinski, T., Effect of enhanced glycemic control with saxagliptin on endothelial nitric oxide release and CD40 levels in obese rats. J. Atheroscler. Thromb. 18:9 (2011), 774–783.